$8.98
0.34% yesterday
Nasdaq, Jun 12, 10:00 pm CET
ISIN
US3984384087
Symbol
GRFS
Sector
Industry

Grifols, S.A. Sponsored ADR Class B Stock price

$8.98
+1.25 16.17% 1M
+1.38 18.16% 6M
+1.54 20.70% YTD
+1.95 27.74% 1Y
-10.24 53.28% 5Y
-6.59 42.33% 10Y
+2.37 35.83% 20Y
Nasdaq, Closing price Thu, Jun 12 2025
+0.03 0.34%
ISIN
US3984384087
Symbol
GRFS
Sector
Industry

Key metrics

Market capitalization $7.45b
Enterprise Value $17.92b
P/E (TTM) P/E ratio 26.41
EV/FCF (TTM) EV/FCF 22.71
EV/Sales (TTM) EV/Sales 2.10
P/S ratio (TTM) P/S ratio 0.87
P/B ratio (TTM) P/B ratio 0.93
Revenue growth (TTM) Revenue growth 10.76%
Revenue (TTM) Revenue $8.54b
EBIT (operating result TTM) EBIT $1.42b
Free Cash Flow (TTM) Free Cash Flow $789.35m
Cash position $1.17b
EPS (TTM) EPS $0.34
P/E forward 11.99
P/S forward 0.87
EV/Sales forward 2.11
Short interest 0.40%
Show more

Is Grifols, S.A. Sponsored ADR Class B a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,845 stocks worldwide.

Grifols, S.A. Sponsored ADR Class B Stock Analysis

Unlock Scores for Free

Analyst Opinions

2 Analysts have issued a Grifols, S.A. Sponsored ADR Class B forecast:

1x Hold
50%
1x Sell
50%

Analyst Opinions

2 Analysts have issued a Grifols, S.A. Sponsored ADR Class B forecast:

Hold
50%
Sell
50%

Financial data from Grifols, S.A. Sponsored ADR Class B

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
8,544 8,544
11% 11%
100%
- Direct Costs 5,231 5,231
10% 10%
61%
3,313 3,313
12% 12%
39%
- Selling and Administrative Expenses 1,406 1,406
2% 2%
16%
- Research and Development Expense 426 426
4% 4%
5%
2,694 2,694
140% 140%
32%
- Depreciation and Amortization 1,271 1,271
1,215% 1,215%
15%
EBIT (Operating Income) EBIT 1,423 1,423
39% 39%
17%
Net Profit 226 226
14% 14%
3%

In millions USD.

Don't miss a Thing! We will send you all news about Grifols, S.A. Sponsored ADR Class B directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Grifols, S.A. Sponsored ADR Class B Stock News

Neutral
GlobeNewsWire
3 days ago
Freising, Germany, June 10, 2025 — XL-protein GmbH, a pioneer in the area of biopolymers for pharmacokinetic optimization, announced today that it has entered into a worldwide License, Development and Commercialization Agreement with Grifols, a global healthcare company and leading manufacturer of plasma-derived medicines, for a novel, long-acting biopharmaceutical product.
Neutral
Business Wire
14 days ago
NEW YORK--(BUSINESS WIRE)--Mason Capital Management LLC (“Mason”), a registered investment advisor to funds and accounts holding approximately 3% of Grifols S.A. (“Grifols” or the “Company”) (BME: GRF) (NASDAQ: GRFS) class A shares, today announced that it sent a letter to the Grifols Board of Directors (the “Board”) expressing Mason's support for the Company's recommended slate of director can...
Positive
Reuters
14 days ago
A New York court found enough evidence to continue with the defamation lawsuit filed by Spanish pharmaceutical company Grifols against short seller Gotham City Research, Grifols said in a statement on Friday.
More Grifols, S.A. Sponsored ADR Class B News

Company Profile

Grifols SA engages in the production of plasma derivatives. It operates through the following segments: Bioscience, Hospital, Diagnostic, Bio Supplies, and Others. The Bioscience Segment includes all activities related with products deriving from human plasma for therapeutic use. The Hospital Segment comprises of all non-biological pharmaceutical products and medical supplies manufactured by group companies earmarked for hospital pharmacy. The Diagnostic Segment deals with the marketing of diagnostic testing equipment, reagents, and other equipment. The Bio Supplies segment consists of all transactions related to biological products for non-therapeutic use. The Others segment focuses on the rendering of manufacturing services to third party companies. The company was founded by José Antonio Grifols Roig on November 18, 1940 and is headquartered in Barcelona, Spain.

Head office Spain
CEO Nacho Abia
Employees 23,833
Founded 1940
Website www.grifols.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today